Wayfinder Biosciences
Wayfinder Biosciences is dedicated to developing a new class of orally available therapeutics by targeting disease-causing mRNA with small molecules. Their innovative platform combines experimental and AI/ML screening to discover selective RNA-targeting small molecules, aiming to treat currently incurable diseases across various indications including oncology, neurodegeneration, immunology, and rare diseases.
Industries
Nr. of Employees
small (1-50)
Products
Pipeline of RNA-targeting small-molecule programs
A portfolio of discovery-stage small-molecule programs targeting disease-relevant mRNAs (publicly listed examples include a program against c-MYC and undisclosed oncology and neurodegeneration programs).
Pipeline of RNA-targeting small-molecule programs
A portfolio of discovery-stage small-molecule programs targeting disease-relevant mRNAs (publicly listed examples include a program against c-MYC and undisclosed oncology and neurodegeneration programs).
Services
Collaborative discovery partnerships for RNA-targeting therapeutics
Collaborative research and development engagements to discover and advance RNA-targeting small-molecule programs across oncology, neurodegeneration, immunology, and rare disease.
Collaborative discovery partnerships for RNA-targeting therapeutics
Collaborative research and development engagements to discover and advance RNA-targeting small-molecule programs across oncology, neurodegeneration, immunology, and rare disease.
Expertise Areas
- RNA-targeted small molecule discovery
- RNA biophysics
- Molecular biology
- Machine learning for drug discovery
Key Technologies
- RNA-based sensors
- AI/ML-driven screening
- Experimental high-throughput screening assays
- Selectivity and functional profiling assays